全築股份(603030.SH):陳文質押的1352萬股延期購回及補充質押80萬股
格隆匯6月1日丨全築股份(603030.SH)公佈,公司近日接到公司持股5%以上的股東陳文的通知,陳文將所質押的部分股份辦理了延期購回及補充質押。
陳文於2019年5月30日將其持有的公司股份1352萬股在國信證券辦理了股票質押式回購交易業務,購回日為2020年5月28日。2020年5月28日陳文將其持有無限售條件流通股80萬股用作對上述質押的補充質押,並對上述股份進行延期購回,購回日為2021年5月27日。此部分補充質押的股份不涉及新的融資安排。
此次補質押後,陳文累計質押公司股份數量為4886萬股,佔其所持公司股份的97.16%,佔公司總股本的9.08%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.